P59: Improvement of Cyclodextran production microbe using Disparity mutagenesis and Ribosome engineering techonology

“Disparity Mutagenesis” is a mutagenesis based on “Disparity evolutional theory” established by Dr. Mitsuru Furusawa, founder of proprietary owner of this technology, Neo-Morgan Laboratory incorporated (hereinafter “NML”). By introducing high error frequency in “Lagging strand” and creating wide diversity similar to spontaneous mutation, Neo-Morgan Laboratory has been improving a variety of microbial activity such as productivity and conversion efficiency.

Prof. Kozo Ochi, professor from Hiroshima Institute of technology, are known for “Ribosome engineering”, which activate the microbial production by improving the protein synthesis during the stationary phase with conferring drug tolerance to ribosome targeting antibiotics.
In this exhibit, we report the result of our collaboration intended to combined these two Japanese origin technologies, to improved the microbial activity of cyclodextran, cyclic isomalto-origosaccharaid known for it’s anti-cariogenic and clathration activity.

Cyclodextran has been long expected for it’s wide application. Although due to the reason such as cost of feedstock, low yield, and complicated process, there has been a difficulty in large-scale production. CI production microbe (T-3040) is known to have direct conversion enzyme from the starch and cyclization enzyme of the dextran. Yet its activity is very low. In this project, we have enhanced the metabolite and growth activity of T-3040, and made further improvement with “Ribosome engineering”. Hence we were able to improve the productivity twice higher than the parental strain.

This work was supported by “The Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry.